Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher(University of Washington), Kevin Lin(Clovis Oncology (United States)), Amit M. Oza(University Health Network), Clare L. Scott(The Royal Melbourne Hospital), Heidi Giordano(Clovis Oncology (United States)), James Sun(Foundation Medicine (United States)), Gottfried E. Konecny(University of California, Los Angeles), Robert L. Coleman(The University of Texas MD Anderson Cancer Center), Anna V. Tinker(BC Cancer Agency), David M. O’Malley(The Ohio State University), Rebecca Kristeleit(London Cancer), Ling Ma(Rocky Mountain Cancer Centers), Katherine M. Bell‐McGuinn(Memorial Sloan Kettering Cancer Center), James D. Brenton(Cancer Research UK), Janiel M. Cragun(University of Arizona), Ana Oaknin(Vall d'Hebron Hospital Universitari), Isabelle Ray‐Coquard(Université Claude Bernard Lyon 1), Maria I. Harrell(University of Washington), Elaina Mann(Clovis Oncology (United States)), Scott H. Kaufmann(Mayo Clinic in Arizona), Anne Floquet(Institut Bergonié), Alexandra Léary(Institut Gustave Roussy), Thomas C. Harding(Clovis Oncology (United States)), Sandra Goble(Clovis Oncology (United States)), Lara Maloney(Clovis Oncology (United States)), Jeff Isaacson(Clovis Oncology (United States)), Andrew R. Allen(Clovis Oncology (United States)), Lindsey Rolfe(Clovis Oncology (United States)), Roman Yelensky(Foundation Medicine (United States)), Mitch Raponi(Clovis Oncology (United States)), Iain A. McNeish(University of Glasgow)
Cited by 1,197Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis